BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
See today's BioWorld Asia
Home
» Boehringer, Hanmi ink $730M deal for EGFR drug for lung cancer
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Boehringer, Hanmi ink $730M deal for EGFR drug for lung cancer
Aug. 5, 2015
By
Pearl Liu
No Comments
HONG KONG – Boehringer Ingelheim GmbH will add to its lung cancer pipeline with a drug from Hanmi Pharmaceutical Co. Ltd. as part of a deal that could, in the end, be worth as much as $730 million to the South Korean firm.
BioWorld Asia